Skip to main content
SpringerLink
Log in

Immunosuppressants and daratumumab

Hypogammaglobulinemiaand lack of efficacy: 2 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Martino R, et al. Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation. Bone Marrow Transplantation 57 : 282-285, No. 2, Feb 2022. Available from: URL: https://www.nature.com/bmt/

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Immunosuppressants and daratumumab. Reactions Weekly 1954, 247 (2023). https://doi.org/10.1007/s40278-023-38065-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-38065-9

Search

Navigation